- Previous Close
0.00 - Open
362.00 - Bid 397.38 x 4000
- Ask 403.73 x 3100
- Day's Range
362.00 - 362.00 - 52 Week Range
261.00 - 496.25 - Volume
10 - Avg. Volume
4 - Market Cap (intraday)
5.184B - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
58.81 - EPS (TTM)
6.16 - Earnings Date May 21, 2025
- Forward Dividend & Yield 2.21 (0.61%)
- Ex-Dividend Date Jul 1, 2024
- 1y Target Est
--
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates through two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
www.ypsomed.comRecent News: YPHDF
View MorePerformance Overview: YPHDF
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: YPHDF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: YPHDF
View MoreValuation Measures
Market Cap
5.18B
Enterprise Value
5.39B
Trailing P/E
58.75
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.08
Price/Book (mrq)
7.03
Enterprise Value/Revenue
7.66
Enterprise Value/EBITDA
29.17
Financial Highlights
Profitability and Income Statement
Profit Margin
12.06%
Return on Assets (ttm)
5.73%
Return on Equity (ttm)
12.44%
Revenue (ttm)
617.07M
Net Income Avi to Common (ttm)
74.39M
Diluted EPS (ttm)
6.16
Balance Sheet and Cash Flow
Total Cash (mrq)
52.31M
Total Debt/Equity (mrq)
52.29%
Levered Free Cash Flow (ttm)
-117.25M